Advair Hfa Aerosol, Metered
Product Images NDC 0173-0715

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Advair Hfa (NDC 0173-0715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Advairhfa Spl Graphic 01)

Chemical structure diagram of fluticasone propionate, one of the active ingredients in ADVAIR HFA. The structure shows various functional groups including hydroxyl, fluorine atoms, and ester moieties, depicted with standard chemical bonds and stereochemistry.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advairhfa Spl Graphic 02)

Chemical structure diagram showing the molecular arrangement of fluticasone propionate and salmeterol xinafoate, the active ingredients in ADVAIR HFA aerosol inhalation.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 03)

A line graph illustrating the percentage change in FEV1 over 12 weeks for four groups: ADVAIR HFA 45 mcg/21 mcg (2 inhalations twice daily), fluticasone propionate 44 mcg (2 inhalations twice daily), salmeterol 21 mcg (2 inhalations twice daily), and placebo. The graph shows treatment progress with patient counts at each time point listed below.*

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Advairhfa Spl Graphic 04)

A line graph depicting percent change in AM peak expiratory flow (PEF) over 12 weeks for three respiratory inhalation treatments: ADVAIR HFA 230 mcg/21 mcg (2 inhalations twice daily), ADVAIR DISKUS 500 mcg/50 mcg (1 inhalation twice daily), and fluticasone propionate inhalation aerosol 220 mcg (2 inhalations twice daily). The x-axis represents weeks, and the y-axis shows percent change in AM PEF.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 05)

A line graph depicting the percentage change in FEV1 over 12 hours for four groups: ADVAIR HFA 45 mcg/21 mcg with two inhalations twice daily, fluticasone propionate inhalation aerosol 44 mcg, salmeterol inhalation aerosol 21 mcg, and placebo. The graph shows time in hours on the x-axis and percent change in FEV1 on the y-axis, illustrating comparative changes in lung function from baseline at Day 1.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 06)

Line graph showing the percent change in FEV1 relative to Day 1 baseline over a 12-hour period for ADVAIR HFA 45 mcg/21 mcg inhalations twice daily and comparator groups, including fluticasone propionate inhalation aerosol, salmeterol inhalation aerosol, and placebo. The graph illustrates lung function improvement trends with different treatments over time.*

FDA Label Image

Figure A (Advairhfa Spl Graphic 07)

An instructional diagram of an ADVAIR HFA aerosol inhaler showing key parts: a metal canister, purple plastic actuator, purple mouthpiece, a counter display, and a light purple protective cap shown separately. The parts are labeled clearly in the illustration.*

FDA Label Image

Figure B (Advairhfa Spl Graphic 08)

An instructional illustration showing a person holding an ADVAIR HFA inhaler in one hand and removing a protective cap with the other hand, demonstrating the preparation steps before use.*

FDA Label Image

Figure C (Advairhfa Spl Graphic 09)

An instructional diagram showing a person using a metered-dose inhaler. The person holds the inhaler upright, pressing down on the top to release a spray, indicated by an arrow and spray cloud. The inhaler has a label marked with the number 125. The cap is shown removed and resting nearby.*

FDA Label Image

Figure D (Advairhfa Spl Graphic 10)

An instructional illustration showing a hand holding a metered-dose inhaler labeled with the number 120, indicating the dose counter. The inhaler is likely associated with ADVAIR HFA, a respiratory aerosol medication by GlaxoSmithKline LLC.*

FDA Label Image

Figure E (Advairhfa Spl Graphic 11)

An instructional illustration showing the correct mouthpiece-down position for using the ADVAIR HFA inhaler. It depicts a hand holding the inhaler with a purple mouthpiece and a light purple cap, labeled with the number 120 on the canister.*

FDA Label Image

Figure F (Advairhfa Spl Graphic 12)

An instructional illustration showing a side profile of a person's face exhaling, accompanied by the text "Breathe out as much air as you can" and an arrow indicating the direction of breath outward from the mouth.*

FDA Label Image

Figure G (Advairhfa Spl Graphic 13)

Instructional diagram showing a person using an inhaler device for respiratory medication. The illustration depicts the correct technique to push down on the inhaler while breathing in the medication through the mouth. The text reads 'Push down and breathe in,' with an arrow indicating the direction of the inhaler actuation.*

FDA Label Image

Figure H (Advairhfa Spl Graphic 14)

This black-and-white illustration shows a person rinsing their mouth with water over a sink. A drinking glass filled with water is visible next to the faucet. The image likely depicts the step of mouth rinsing after using an inhalation aerosol product.*

FDA Label Image

Figure I (Advairhfa Spl Graphic 15)

An instructional diagram showing proper and improper use of an aerosol inhaler. The top image labeled 'Not blocked' depicts the inhaler correctly releasing medication. The bottom image labeled 'Blocked' shows the inhaler's opening obstructed, preventing medication release.*

FDA Label Image

Advair Hfa 45mcg 120 Dose Carton (Advairhfa Spl Graphic 16)

An instructional illustration showing a hand using a cotton swab to clean the mouthpiece of an inhaler device by rotating the swab inside the opening.*

FDA Label Image

Advair Hfa 115mcg 120 Dose Carton (Advairhfa Spl Graphic 17)

Label for ADVAIR HFA inhalation aerosol containing fluticasone propionate and salmeterol xinafoate with strength 45 mcg/21 mcg per actuation. The label includes usage instructions, content description, prescription-only status, and an image of the purple metered dose inhaler. The net weight is 12 g with 120 metered actuations. Labeler is GlaxoSmithKline LLC.*

FDA Label Image

Advair Hfa 230mcg 120 Dose Carton (Advairhfa Spl Graphic 18)

Label for ADVAIR HFA aerosol inhalation suspension containing 115 mcg fluticasone propionate and 21 mcg salmeterol per actuation. The label includes dosage form as inhalation aerosol, quantity of 120 metered actuations with net weight 12 g, and is labeled for prescription use only. Manufactured by GlaxoSmithKline LLC.*

FDA Label Image

Advairhfa Spl Graphic 19

Label for ADVAIR HFA inhalation aerosol, containing fluticasone propionate and salmeterol. The strength is 230 mcg/21 mcg per actuation. The label indicates the product is for oral inhalation with ADVAIR HFA actuator only, contains 120 metered actuations with a net weight of 12 g, and is manufactured by GlaxoSmithKline LLC. The label includes usage instructions and prescription only status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.